Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856917 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 15
- Study locations
NCT04856917: Completed Phase 2 study of Acne Vulgaris, sponsored by Vanda Pharmaceuticals.
NCT04856917 is a Phase 2 study of Acne Vulgaris that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 123 participants, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (55% lower). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04856917, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 15
- Study locations
Study Summary
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
Primary Outcome
The number of facial inflammatory lesions (pustules, papules, and nodular lesions) on the forehead, left and right cheeks, nose, and chin were counted. Baseline was defined as the last available measurement taken prior to the first dose of study treatment.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- DRUG Imsidolimab
Study Locations (15)
Florida
- Site 10-113 - Sweetwater
- Site 10-108 - Tampa
- Site 10-107 - Tampa
Texas
- Site 10-103 - Austin
- Site 10-102 - College Station
- Site 10-101 - San Antonio
California
- Site 10-111 - Fountain Valley
- Site 10-106 - Sherman Oaks
Louisiana
- Site 10-109 - New Orleans
- Site 10-112 - New Orleans
Arkansas
- Site 10-114 - Hot Springs
Michigan
- Site 10-104 - Detroit
New Hampshire
- Site 10-110 - Portsmouth
Tennessee
- Site 10-105 - Murfreesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2022-03-29 |
| Phase | Phase 2 |
What the finished NCT04856917 record still lists
NCT04856917 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04856917 lists 15 locations in 9 states (Florida, Texas, California).
Frequently Asked Questions
What is clinical trial NCT04856917 about?
NCT04856917 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris". Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
What is the current status of trial NCT04856917?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2021-05-15. Estimated completion is 2022-03-29.
What conditions does trial NCT04856917 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT04856917?
The interventions under investigation include: Placebo (BIOLOGICAL), Imsidolimab (DRUG).
Who is sponsoring clinical trial NCT04856917?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04856917 being conducted?
This trial has 15 study locations across Arkansas, California, Florida, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04856917's enrollment target sits among peer trials
123 36th of 67 higher than 31 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI